OrsoBio, Inc., a Menlo Park, CA-based clinical-stage biopharmaceutical company developing treatments for obesity and obesity-associated disorders, closed a $67m Series B financing.
The round was co-led by new investors Ascenta Capital and Woodline Partners, with significant participation from existing investors Samsara Biocapital, Longitude Capital, Enavate Sciences, NuevaBio, and Eli Lilly and Company. In conjunction with the financing, Evan Rachlin, MD, Co-Founder and Managing Partner of Ascenta Capital, joined the OrsoBio Board of Directors.
The company intends to use the funds to accelerate development of its mitochondrial protonophore portfolio for the treatment of obesity and associated metabolic disorders.
Led by Mani Subramanian, MD, PhD, CEO and Founder, OrsoBio is a clinical-stage biopharmaceutical company dedicated to developing therapies to treat obesity and obesity-associated disorders, including type 2 diabetes, MASH, and severe dyslipidemias. The company currently has four programs in clinical and preclinical development with first-in-class compounds that address central pathways in energy metabolism.
The portfolio of compounds in clinical development includes:
- TLC-6740, a novel, oral, liver-targeted mitochondrial protonophore under evaluation in a 12-week, Phase 1b clinical trial in patients living with obesity (NCT05822544),
- TLC-1180, a potent, long-acting mitochondrial protonophore that is suitable for weekly oral or subcutaneous administration,
- TLC-1235, a controlled-release mitochondrial protonophore (CRMP) that has shown metabolic benefits across a range of models and species,
- TLC-3595, an ACC2 inhibitor, currently in a Phase 2a study for the treatment of type 2 diabetes, and
- TLC-2716, a liver X receptor (LXR) inverse agonist currently in a Phase 2a study for severe hypertriglyceridemia and MASH.
FinSMEs
09/09/2024